40 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26190460	2	Chemical synthesis of tetracyclic terpenes and evaluation of antagonistic activity on endothelin-A receptors and voltage-gated calcium channels.	Kansas State University
25614116	13	Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity.	Southeast University
11809055	1	New chlorinated diphenyl ethers from an Aspergillus species.	University of Western Australia
15055997	42	Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.	Encysive Pharmaceuticals
11585442	20	Potent and selective ET-A antagonists. 2. Discovery and evaluation of potent and water soluble N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.	Tanabe Seiyaku
9857090	158	Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308).	Bristol-Myers Squibb Pharmaceutical Research Institute
9667964	38	Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.	Rh£Ne-Poulenc Rorer
1315867	31	Endothelin: a new challenge.	Warner-Lambert
9873432	52	Endothelin antagonists: discovery of EMD 122946, a highly potent and orally active ETA selective antagonist.	Merck
	23	Structure-activity relationships of monocyclic endothelin analogs	TBA
	10	A Novel Class of Non-Peptidic Endothelin Antagonists Isolated from the Medicinal Herb Phyllanthus niruri	TBA
	56	Pyridazinones with a pendant acylsulfonamide moiety as endothelin receptor antagonists	TBA
	26	1,4-Diaryl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acids as endothelin receptor antagonists	TBA
	32	Quantitative structure-activity relationships study of endothelin-1 analogs	TBA
	25	Structure-activity relationships in a series of monocyclic endothelin analogues	TBA
15139753	55	Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists.	University of Innsbruck
11985472	185	Structure-activity relationships of a novel class of endothelin-A receptor antagonists and discovery of potent and selective receptor antagonist, 2-(benzo[1,3]dioxol-5-yl)-6-isopropyloxy-4-(4-methoxyphenyl)-2H-chromene-3-carboxylic acid (S-1255). 1. Study on structure-activity relationships and bas	Shionogi
11689084	47	Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.	Abbott Laboratories
11585441	70	Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.	Tanabe Seiyaku
11086733	56	Potent nonpeptide endothelin antagonists: synthesis and structure-activity relationships of pyrazole-5-carboxylic acids.	Hoechst Marion Roussel
10969989	45	Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.	Shionogi
27266371	13	Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.	Centre Hospitalier Universitaire Vaudois (Chuv)
10890162	52	Nonpeptide endothelin antagonists: from lower affinity pyrazol-5-ols to higher affinity pyrazole-5-carboxylic acids.	Hoechst Marion Roussel
27321813	286	From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.	Actelion Pharmaceuticals
10715156	35	Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives.	RhôNe-Poulenc Rorer
10098676	52	Benzofuro[3,2-b]pyridines as mixed ET(A)/ET(B) and selective ET(B) endothelin receptor antagonists.	Merck
9871621	26	Endothelin antagonists: evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster.	Merck
9703472	112	Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).	Abbott Laboratories
9667965	29	Selective endothelin A receptor antagonists. 4. Discovery and structure-activity relationships of stilbene acid and alcohol derivatives.	RhôNe-Poulenc Rorer
9379441	100	Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.	Abbott Laboratories
9022798	58	Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists.	Abbott Laboratories
8676339	143	2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.	Abbott Laboratories
8632420	112	Azole endothelin antagonists. 2. Structure-activity studies.	Abbott Laboratories
8632419	50	Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile.	Abbott Laboratories
8308857	19	The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide.	Bristol-Myers Squibb Pharmaceutical Research Institute
7861414	36	Three-dimensional quantitative structure-activity relationships of sulfonamide endothelin inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
7731020	87	Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.	Bristol-Myers Squibb Pharmaceutical Research Institute